New hope for rare brain disorder: drug trial targets PSP progression
NCT ID NCT07498426
First seen Apr 04, 2026 · Last updated May 04, 2026 · Updated 6 times
Summary
This study tests an experimental drug called NIO752 in 300 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement, balance, and swallowing. Participants will receive either NIO752 or a placebo to see if the drug can slow the disease. The study is for adults aged 41-81 with mild to moderate PSP.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY RICHARDSON SYNDROME (PSP-RS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.